The United Kingdom and the United States have concluded a significant trade agreement that will guarantee zero levies on UK medicine shipments going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these crucial exports will stay at nothing for a timeframe of the next three years.
This development comes after previous statements to dramatically increase import taxes on branded pharmaceutical imports, with figures mentioned as high as 100%.
"This arrangement with the United Kingdom strengthens the global environment for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Importance
Pharmaceuticals represent one of the Britain's largest exports to the United States, which is easily the biggest market for large UK drugmakers.
Statistics indicate that in the one-year period prior to last September, the UK sold drugs valued at £11.1bn to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This deal secures work, increases investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Key British Pledges
The deal includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
This agreement follows a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were intensified by claims that US consumers were charged significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward American operations.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
